Neurology & Neurosurgery Research
Interventional Dementia Study
This study is currently closed to enrollment.
Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
AGE: 25 – 85 years old
GENDER: All
GENDER: All
TYPE: Interventional Drug Study
CONDITION: Frontotemporal Lobar Degeneration/Frontotemporal Dementia
CONDITION: Frontotemporal Lobar Degeneration/Frontotemporal Dementia
LOCATIONS: UH Cleveland Medical Center, UH Brain Health and Memory Center
DEPARTMENT: Neurology
DEPARTMENT: Neurology
Purpose of the Study
The purpose of this Phase 3 study is to determine if the experimental drug AL001 is effective and safe in treating individuals who have a progranulin gene mutation that causes Frontotemporal Dementia (FTD), when compared to placebo (a solution that contains no active AL001 drug).